NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis $31.35 +3.09 (+10.93%) Closing price 08/25/2026 04:00 PM EasternExtended Trading$31.90 +0.55 (+1.76%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About ArriVent BioPharma Stock (NASDAQ:AVBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ArriVent BioPharma alerts:Sign Up Key Stats Today's Range$28.64▼$31.5250-Day Range$28.22▼$34.7452-Week Range$17.00▼$35.83Volume961,652 shsAverage Volume403,898 shsMarket Capitalization$1.55 billionP/E RatioN/ADividend YieldN/APrice Target$44.86Consensus RatingModerate Buy Company Overview ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania. Read More ArriVent BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreAVBP MarketRank™: ArriVent BioPharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 586th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArriVent BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialArriVent BioPharma has a consensus price target of $44.86, representing about 43.1% upside from its current price of $31.35.Amount of Analyst CoverageArriVent BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ArriVent BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ArriVent BioPharma are expected to grow in the coming year, from ($4.01) to ($3.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ArriVent BioPharma is -8.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ArriVent BioPharma is -8.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArriVent BioPharma has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.25% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 21.76, which indicates bearish sentiment.Change versus previous monthShort interest in ArriVent BioPharma has recently increased by 2.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.47 News SentimentArriVent BioPharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for ArriVent BioPharma this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AVBP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.58% of the stock of ArriVent BioPharma is held by insiders.Percentage Held by Institutions9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVBP Stock News HeadlinesHC Wainwright Issues Negative Forecast for AVBP EarningsAugust 21, 2026 | americanbankingnews.comFY2027 Earnings Forecast for AVBP Issued By HC WainwrightAugust 20, 2026 | americanbankingnews.comI thought I’d seen stupid (pic attached)A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natural gas to Boston. The odd part: the Marcellus Shale, one of the largest natural gas reserves in the world, sits just a few hundred miles away. Porter Stansberry spent years digging into why this happens and what it means for the American energy system.August 26 at 1:00 AM | Porter & Company (Ad)HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma (NASDAQ:AVBP) StockAugust 19, 2026 | americanbankingnews.comGuggenheim Reiterates "Buy" Rating for ArriVent BioPharma (NASDAQ:AVBP)August 15, 2026 | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Earns Buy Rating from BTIG ResearchAugust 15, 2026 | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 4.7% After Earnings MissAugust 15, 2026 | americanbankingnews.comArriVent inks China partnership for ARR-002 developmentAugust 12, 2026 | tipranks.comSee More Headlines AVBP Stock Analysis - Frequently Asked Questions How have AVBP shares performed this year? ArriVent BioPharma's stock was trading at $20.12 at the start of the year. Since then, AVBP stock has increased by 55.8% and is now trading at $31.35. How were ArriVent BioPharma's earnings last quarter? ArriVent BioPharma, Inc. (NASDAQ:AVBP) announced its earnings results on Wednesday, August, 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.06. When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an IPO on Thursday, January 25th 2024. The company issued 9,722,222 shares at a price of $17.00-$19.00 per share. Who are ArriVent BioPharma's major shareholders? Top institutional shareholders of ArriVent BioPharma include Montanova Capital LLC (9.16%), Hhlr Advisors LTD. (8.44%), BlackRock Inc. (6.98%) and General Catalyst Group Management LLC (3.21%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ArriVent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/12/2026Today8/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 AVBP's financial health is in the Green zone, according to TradeSmith. AVBP has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for ArriVent BioPharma$44.86 High Price Target$50.00 Low Price Target$40.00 Potential Upside/Downside+43.1%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$166.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.26% Return on Assets-46.66% Debt Debt-to-Equity RatioN/A Current Ratio14.16 Quick Ratio14.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.44 per share Price / Book4.21Miscellaneous Outstanding Shares49,310,000Free Float45,077,000Market Cap$1.55 billion OptionableN/A Beta1.36 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AVBP) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredNear retirement? Buy this stockOn August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of ...Stansberry Research | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
